CONTRACT AMENDMENT BUSINESS: NewLink Genetics Corporation MASTER CONTRACT #: 04-IVF-019 AMENDMENT #: One EFFECTIVE DATE: August 19, 2010

EX-10.57 58 a2200411zex-10_57.htm EX-10-57

Exhibit 10.57

 

CONTRACT AMENDMENT

 

BUSINESS:

 

NewLink Genetics Corporation

MASTER CONTRACT #:

 

04-IVF-019

AMENDMENT #:

 

One

EFFECTIVE DATE:

 

August 19, 2010

 

THIS CONTRACT AMENDMENT is made by and between the IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT, (hereafter “Department” or “IDED”), 200 East Grand Avenue, Des Moines, Iowa 50309, an agency of the State of Iowa and NewLink Genetics Corporation (hereafter “Business”), a Delaware corporation, 2901 South Loop Drive, Suite 3900, Ames, Iowa 50010.

 

WHEREAS, Business requested an extension of the Project Completion Date, and

 

WHEREAS, the IDED Board approved a one (1) year extension, effective as of the Effective Date stated above, and

 

NOW, THEREFORE, the Contract referenced above is amended as follows:

 

1.              REVISION OF ARTICLE 10.2, “COVENANTS.”  Article 10.2 is amended as follows:

 

10.2                Creation and Maintenance of Jobs in Iowa.
(a)  By March 18, 2011  the end of the 5th year from the Contract Effective Date plus any additional extension periods that may be granted by IDED pursuant to this Article 10.2, the Business shall create 315 jobs and retain 35 jobs for a total of 350 jobs (the “Job Creation/Retention Obligation”).  One hundred percent (100%) of the pledged jobs shall be created by March 18, 2011 the end of the 5th year from the Contract Effective Date.  At that time, the 5-year Job Maintenance Period shall begin, ending March 18, 2016. The combined Job Creation Period time frame and the Job Maintenance Period shall be the end of the 10th year from the Contract Effective Date plus any additional extension periods that may be granted by IDED pursuant to this Article 10.2.  All Project jobs shall be created and maintained in the State of Iowa.

 

2.              REVISION OF EXHIBIT D,  “DESCRIPTION OF THE PROJECT AND AWARD BUDGET.”  Exhibit D is amended to revise the Project Completion Date.  Details of this change are reflected in the attached Revised Exhibit C which is hereby incorporated by this reference and made a part of this Contract Amendment.

 

This section left blank intentionally; signature page follows.

 



 

Except as otherwise revised above, the terms, provisions, and conditions of Contract Number 04-IVF-019 remain unchanged and are in full force and effect:

 

 

FOR BUSINESS:

 

FOR IDED:

 

 

 

 

 

 

 

 

Brett Mills, Director

DATE

SIGNATURE

 

 

 

 

 

 

 

 

PRINT/TYPE NAME, TITLE

 

 

 

 

 

 

 

 

FOR COMMUNITY:

 

 

 

 

 

 

 

 

SIGNATURE

 

 

 

 

 

 

 

 

PRINT/TYPE NAME, TITLE

 

 

 


 

GROW IOWA VALUE FUNDS PROGRAM

PROJECT DESCRIPTION AND BUDGET

(EXHIBIT D)

 

 

To be filled in by DED:                  

 

 

 

 

Original                      

 

 

 

Name of Recipient:

NewLink Genetics

Amendment #                    

 

 

 

Contract #:

04-IVF-19

 

 

PROJECT DESCRIPTION

 

NewLink Genetics, Inc. will develop and bring to market cancer drugs, diagnostic applications and software databases. The project involves bringing at least 3 cancer drugs to clinical trials, initiating collaborative product development with another pharmaceutical/biotech companies, building a pharmaceutical research and development facility, and constructing a pharmaceutical manufacturing plant.

 

PERFORMANCE TARGETS

 

NewLink Genetics will invest at least $189,862,500 in research and development of cancer drugs; acquisition of equipment; construction of a R & D facility and product manufacturing facility.  NewLink Genetics will retain 35 employees and create 315 positions within 5 years of the Contract Effective Date by the Project Completion Date.

 

PROJECT COMPLETION DATE: 5 Years from Contract Effective Date March 18, 2011

PROJECT MAINTENANCE DATE: 10 Years From Contract Effective Date March 18, 2016

 

AMOUNT BUDGETED

 

USE OF FUNDS
ACTIVITY

 

Cost

 

Source A

 

Source B

 

Source C

 

Source D

 

Source E

 

Source F

 

Clinical Trials

 

$

55,300,000

 

 

 

$

55,300,000

 

 

 

 

 

 

 

 

 

Product Devel/Testing

 

$

2,500,000

 

$

1,507,500

 

 

 

 

 

$

992,500

 

 

 

 

 

Research & Development

 

$

78,750,000

 

$

2,000,000

 

$

76,250,000

 

 

 

$

500,000

 

 

 

 

 

Capital Equipment Acq.

 

$

12,100,000

 

$

1,600,000

 

$

10,500,000

 

 

 

 

 

 

 

 

 

Building Construction

 

$

20,300,000

 

$

492,500

 

$

19,300,000

 

 

 

 

 

$

507,500

 

 

 

Bioinformatics Equipment/

 

$

5,750,000

 

$

400,000

 

$

5,350,000

 

 

 

 

 

 

 

 

 

Database Equipment

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Training (260E)

 

$

1,930,000

 

 

 

 

 

$

1,930,000

 

 

 

 

 

 

 

Other Capital Investment

 

$

13,232,000

 

 

 

$

8,950,000

 

 

 

$

4,282,500

 

 

 

 

 

 

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL

 

$

189,862,500

 

$

6,000,000

 

$

175,650,000

 

$

1,930,000

 

$

5,775,000

 

$

507,500

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL

 

$

0

 

$

0

 

$

0

 

$

0

 

$

0

 

$

0

 

$

0

 

TOTAL ALL FUNDS

 

$

189,862,500

 

$

6,000,000

 

$

175,650,000

 

$

1,930,000

 

$

5,775,000

 

$

507,500

 

$

0

 

 

TERMS OF PROPOSED FINANCING

 

Source of Funds

 

Amount

 

Type

 

Rate

 

Term

 

Collateral

Source A: Iowa Values Fund

 

$

6,000,000

 

Fgl/Royalty

 

 

 

 

 

1st position on Intellectual Property, $3.2 million royalty repayment to be paid back

Source B: NewLink Genetics Inv/Equity

 

$

175,650,000

 

Tax Refund

 

 

 

 

 

Source C: New Jobs Training Fund

 

$

1,930,000

 

Grant

 

 

 

 

 

Source D: NCIP/NJIP

 

$

5,775,000

 

Tax Credits

 

 

 

 

 

within ten years.

Source E: NCIP/NJIP

 

$

507,500

 

Sales Tax Refund

 

 

 

 

 

 

Source F:

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL:

 

$

189,862,500

 

 

 

 

 

 

 

 

 

ADDITIONAL PERFORMANCE TARGETS

 

Number of Jobs to be Created:

 

315

 

Total of other Funds in Project:

 

$183,862,500

Number of Jobs to be Retained:

 

35

 

 

 

 

Total GIVF for Project:

 

$6,000,000

 

Total GIVF for Project:

 

    $6,000,000

 

 

 

 

 

 

 

GIVF per Job Affected:

 

$17,142.86

 

Ratio of $1.00 of GIVF to:

 

$30.64 of “Other” Funds